172: Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions
D. Avigan, Donald Küfe(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), C. Lenahan(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Paul G. Richardson(Harvard University), Nikhil C. Munshi(Dana-Farber Cancer Institute), D. Donbagoda(Hadassah Medical Center), Claire MacNamara, Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), K. Miller(Hadassah Medical Center), Baldev Vasir(Beth Israel Deaconess Medical Center), Karen Lowe, Z. Wu(Dana-Farber Cancer Institute), James D. Levine(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k